Veru (NASDAQ:VERU) Price Target Lowered to $24.00 at Oppenheimer
by Doug Wharley · The Cerbat GemVeru (NASDAQ:VERU – Get Free Report) had its target price decreased by investment analysts at Oppenheimer from $25.00 to $24.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock.
A number of other research analysts have also recently commented on the stock. Wall Street Zen cut shares of Veru from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research note on Monday, April 20th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Veru has an average rating of “Moderate Buy” and an average target price of $23.00.
Read Our Latest Analysis on VERU
Veru Price Performance
VERU opened at $2.08 on Friday. The company has a market capitalization of $33.38 million, a P/E ratio of -1.65 and a beta of -1.19. The firm’s fifty day moving average price is $2.34 and its two-hundred day moving average price is $2.44. Veru has a fifty-two week low of $2.05 and a fifty-two week high of $7.40.
Veru (NASDAQ:VERU – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.15. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $1.90 million. On average, equities research analysts expect that Veru will post -1.43 EPS for the current fiscal year.
Hedge Funds Weigh In On Veru
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sender Co & Partners Inc. boosted its position in shares of Veru by 82.8% during the second quarter. Sender Co & Partners Inc. now owns 238,231 shares of the company’s stock worth $139,000 after purchasing an additional 107,911 shares in the last quarter. Raymond James Financial Inc. increased its position in shares of Veru by 48.3% in the 2nd quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after buying an additional 67,178 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Veru during the 3rd quarter worth $110,000. Bank of America Corp DE raised its stake in Veru by 5.5% during the 2nd quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock worth $108,000 after buying an additional 9,637 shares during the period. Finally, Blair William & Co. IL lifted its holdings in Veru by 26.3% during the fourth quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock worth $103,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 47.16% of the company’s stock.
About Veru
Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.
The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.